We read with interest the article
by Yamamoto et al1 on the impact of
infliximab after early endoscopic postsurgical
recurrence of Crohn’s disease
(CD) published in the current issue of
IBD. Although this study adds timely
information to an exciting field, we
believe that, for the time being, it
should be interpreted with caution.
Current knowledge on prevention of
postsurgical recurrence of CD by
infliximab stems from reports from our
group as well as from a small randomized
controlled trial (RCT) by Regueiro
et al.2,3 Although these data
would benefit from confirmation by a
large trial, they uniformly show that
therapy with this biologic—initiated
immediately after surgery—prevents
endoscopic and clinical recurrence of
disease in the large majority of
patients.
